Zobrazeno 1 - 10
of 26
pro vyhledávání: '"David W. Lafleur"'
Autor:
David M. Hilbert, Laura K. Richman, David A. Tice, David W. LaFleur, Ankit Gupta, Alexandra R. Witter, Liubov Zaritskaya, Justin P. Edwards, Janine M. Buonato
Chimeric antigen receptor (CAR) T-cell therapies directed against B-cell maturation antigen (BCMA) have shown compelling clinical activity and manageable safety in subjects with relapsed and refractory multiple myeloma (RRMM). Prior reported CAR T ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71900aff4b530f83223fd73889180fb3
https://doi.org/10.1158/1535-7163.c.6543447
https://doi.org/10.1158/1535-7163.c.6543447
Autor:
David M. Hilbert, Laura K. Richman, David A. Tice, David W. LaFleur, Ankit Gupta, Alexandra R. Witter, Liubov Zaritskaya, Justin P. Edwards, Janine M. Buonato
Supplementary Figure from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed9c9f3f2958d7eb79a0389dba021a3
https://doi.org/10.1158/1535-7163.22522638.v1
https://doi.org/10.1158/1535-7163.22522638.v1
Autor:
David M. Hilbert, Laura K. Richman, David A. Tice, David W. LaFleur, Ankit Gupta, Alexandra R. Witter, Liubov Zaritskaya, Justin P. Edwards, Janine M. Buonato
Supplementary Data from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f624cb11aaa983a354be119709d9bba
https://doi.org/10.1158/1535-7163.22522644
https://doi.org/10.1158/1535-7163.22522644
Autor:
David M. Hilbert, Laura K. Richman, David A. Tice, David W. LaFleur, Ankit Gupta, Alexandra R. Witter, Liubov Zaritskaya, Justin P. Edwards, Janine M. Buonato
Supplementary Table from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b2653483a09b31ace2084c42b028979
https://doi.org/10.1158/1535-7163.22522617
https://doi.org/10.1158/1535-7163.22522617
Autor:
C. Jenny Mu, Justin P. Edwards, Haiying Qin, David M. Hilbert, David W. Lafleur, Terry J. Fry, Ankit Gupta, Liubov Zaritskaya
Publikováno v:
Mol Ther
Chimeric antigen receptor (CAR) T cell therapies have demonstrated impressive initial response rates in hematologic malignancies. However, relapse rates are significant, and robust efficacies in other indications, such as solid tumors, will likely re
Autor:
Janine M. Buonato, Justin P. Edwards, Liubov Zaritskaya, Alexandra R. Witter, Ankit Gupta, David W. LaFleur, David A. Tice, Laura K. Richman, David M. Hilbert
Publikováno v:
Molecular cancer therapeutics. 21(7)
Chimeric antigen receptor (CAR) T-cell therapies directed against B-cell maturation antigen (BCMA) have shown compelling clinical activity and manageable safety in subjects with relapsed and refractory multiple myeloma (RRMM). Prior reported CAR T ce
Autor:
David A. Tice, Jeffrey S. Swers, Justin P. Edwards, Sinnie Ng, David M. Hilbert, Haiyan Wang, David W. Lafleur, Samantha McCullough, Janine M Buonato, Liubov Zaritskaya, Ankit Gupta, Jenny Mu
Publikováno v:
Cancer Research. 81:1549-1549
Genetically engineered T cells have demonstrated great promise in the treatment of hematologic malignancies including Acute Lymphocytic Leukemia, Non-Hodgkin's lymphoma, and Multiple Myeloma. However, those achievements are often associated with unco
Autor:
Terry J. Fry, Haiying Qin, David W. Lafleur, C. Jenny Mu, Laura K. Richman, Justin P. Edwards, Ankit Gupta, David M. Hilbert, Liubov Zaritskaya
Publikováno v:
Cancer Research. 80:601-601
Unlike the tumor targets associated with initial CAR T cell successes, the vast majority of tumor associated antigens are not unique, but rather expressed at elevated levels compared to normal tissue. For example, while CD123 is overexpressed on many
Autor:
Liubov Zaritskaya, Ankit Gupta, David M. Hilbert, Jeffrey Swers, Jenny Mu, Justin P. Edwards, Laura Richman, David W. Lafleur
Publikováno v:
Journal of Clinical Oncology. 38:3041-3041
3041 Background: Conventional chimeric antigen receptor T cell (CAR-T) therapies have achieved limited clinical success in the treatment of solid tumors, in part due to the challenges of identifying tumor antigen(s) that are uniquely expressed on tum
Publikováno v:
Monoclonal Antibodies: Development, Delivery and Applications. :24-38